NOVEMBER – DECEMBER 2024 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
EMA December 30 – Lazertinib + amivantamab – NSCLC EGFR. The European Commission (EC) has approved a Type II variation extension of indication for amivantamab (anti-EGFR-MET bispecific antibody), in combination with lazertinib (third-generation EGFR tyrosine kinase inhibitor), for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor […]